A correlativity study of plasma APL1β28 and clusterin levels with MMSE/MoCA/CASI in aMCI patients.
Amnestic mild cognitive impairment (aMCI) is a sub-clinical condition characterized by memory deficits that are not severe enough to affect daily functioning. Here we investigated two potential biomarkers found in the cerebrospinal fluid of AD patients, APLP1-derived Aβ-like peptides 28 (APL1β28) and clusterin plasma levels, in terms of their relationship to cognitive function, as reflected in the Mini-Mental State Examination (MMSE), the Montreal Cognitive Assessment (MoCA) and the Cognitive Assessment Screening Instrument (CASI) in aMCI patients. Forty-seven aMCI patients and thirty-five age- and gender-matched healthy adult controls were recruited for this study. Using the ELISA method, we found that the mean concentrations of both APL1β28 and clusterin were not significantly different between the control and aMCI groups. The APL1β28 levels were positively correlated with clusterin and that both were negatively correlated with the MMSE scores of the aMCI patients. Clusterin levels were negatively correlated with the MoCA and CASI scores of the aMCI patients. Using multivariate analysis, the correlation between clusterin and MMSE/MoCA/CASI was independent of other AD risk factors including age, education, sex, body mass index and ApoE genotype. The data presented here demonstrate that plasma clusterin levels reflect cognitive function in aMCI patients.
Dementia Care &Research Center, Peking University Institute of Mental Health; Beijing Municipal Key Laboratory for Translational Research on Diagnosis and Treatment of Dementia, National Clinical Research Center for Mental Disorders (Peking University Sixth Hospital), Peking University.|State Key Laboratory of Membrane Biology, School of Life Sciences; PKU-IDG/McGovern Institute for Brain Research, Peking University, Beijing 100871, China.
Ying
Y
Meng
Dementia Care &Research Center, Peking University Institute of Mental Health; Beijing Municipal Key Laboratory for Translational Research on Diagnosis and Treatment of Dementia, National Clinical Research Center for Mental Disorders (Peking University Sixth Hospital), Peking University.|State Key Laboratory of Membrane Biology, School of Life Sciences; PKU-IDG/McGovern Institute for Brain Research, Peking University, Beijing 100871, China.
Huiying
H
Li
State Key Laboratory of Membrane Biology, School of Life Sciences; PKU-IDG/McGovern Institute for Brain Research, Peking University, Beijing 100871, China.
Rui
R
Hua
Dementia Care &Research Center, Peking University Institute of Mental Health; Beijing Municipal Key Laboratory for Translational Research on Diagnosis and Treatment of Dementia, National Clinical Research Center for Mental Disorders (Peking University Sixth Hospital), Peking University.
Huali
H
Wang
State Key Laboratory of Membrane Biology, School of Life Sciences; PKU-IDG/McGovern Institute for Brain Research, Peking University, Beijing 100871, China.
Jian
J
Lu
Dementia Care &Research Center, Peking University Institute of Mental Health; Beijing Municipal Key Laboratory for Translational Research on Diagnosis and Treatment of Dementia, National Clinical Research Center for Mental Disorders (Peking University Sixth Hospital), Peking University.
Xin
X
Yu
State Key Laboratory of Membrane Biology, School of Life Sciences; PKU-IDG/McGovern Institute for Brain Research, Peking University, Beijing 100871, China.
Chen
C
Zhang
D000368:Aged; D016564:Amyloid beta-Protein Precursor / Q000097:blood*; D051152:Clusterin / Q000097:blood*; D060825:Cognitive Dysfunction / Q000097:blood*; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D008297:Male; D009483:Neuropsychological Tests; D010446:Peptide Fragments / Q000097:blood*
C000611045:APL1beta28 peptide, human; D016564:Amyloid beta-Protein Precursor; D051152:Clusterin; D010446:Peptide Fragments